Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

3 Sep 2007 07:00

Avacta Group plc

Development Contract with the MOD's Defence science and technology laboratory

Field Detection of Liquid Chemicals

Avacta Group plc ("Avacta"), which develops detection and analysis technology aimed at the defence & security, pharmaceutical and clinical diagnostics markets, announces a contract with the Defence science and technology laboratory (Dstl), which is part of the UK Ministry of Defence.

Avacta is developing methods of analysing liquids using laser spectroscopy. The goal is to enable the rapid detection of liquids in the field.

Professor Alastair Smith, Chief Executive, Avacta, commented:

"We are delighted with the new contract for the development of a robust, prototype device. Laser detection and diagnostic devices are a key part of Avacta's portfolio of technologies and this contract with the MOD is an important step for the company."

3 September 2007Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk W.H. Ireland Ltd Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7099 1942 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes. A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

AVACTA GROUP PLC
Date   Source Headline
15th Jun 20204:36 pmRNSPrice Monitoring Extension
15th Jun 20202:05 pmRNSSecond Price Monitoring Extn
15th Jun 20202:00 pmRNSPrice Monitoring Extension
15th Jun 202011:05 amRNSSecond Price Monitoring Extn
15th Jun 202011:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20206:35 pmRNSHolding(s) in Company
9th Jun 20207:01 amRNSInvestor Presentation
9th Jun 20207:00 amRNSUpdate on COVID-19 Test Development with Adeptrix
8th Jun 20204:15 pmRNSPosting of Circular and Notice of General Meeting
4th Jun 20205:16 pmRNSDirector/PDMR Shareholding
4th Jun 20205:15 pmRNSResult of Fundraising
4th Jun 202012:30 pmRNSIncrease in Fundraising
4th Jun 202011:05 amRNSSecond Price Monitoring Extn
4th Jun 202011:00 amRNSPrice Monitoring Extension
4th Jun 20209:05 amRNSSecond Price Monitoring Extn
4th Jun 20209:00 amRNSPrice Monitoring Extension
4th Jun 20207:01 amRNSPrimaryBid.com Offers
4th Jun 20207:00 amRNSProposed Fundraising to raise up to £45 million
28th May 20207:00 amRNSPosting of Annual Report and Notice of AGM
26th May 202011:05 amRNSSecond Price Monitoring Extn
26th May 202011:00 amRNSPrice Monitoring Extension
26th May 20208:06 amRNSIssue of Equity
21st May 20202:05 pmRNSSecond Price Monitoring Extn
21st May 20202:00 pmRNSPrice Monitoring Extension
20th May 20207:00 amRNSDistribution Agreement for COVID-19 Antigen Test
15th May 20204:41 pmRNSSecond Price Monitoring Extn
15th May 20204:35 pmRNSPrice Monitoring Extension
15th May 20202:06 pmRNSSecond Price Monitoring Extn
15th May 20202:00 pmRNSPrice Monitoring Extension
15th May 202011:06 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
15th May 20209:30 amRNSIssue of Equity
15th May 20207:00 amRNSSARS-COV-2 Neutralising Affimers
11th May 20207:00 amRNSAvacta Ships SARS-COV-2 Affimer Reagents
6th May 20207:00 amRNSResults for the period ending 31 December 2019
5th May 20206:15 pmRNSHolding(s) in Company
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSCOVID-19 Antigen Test Collaboration with Adeptrix
27th Apr 20205:30 pmRNSHolding(s) in Company
27th Apr 20205:00 pmRNSHolding(s) in Company
24th Apr 20206:00 pmRNSHolding(s) in Company
24th Apr 20204:41 pmRNSSecond Price Monitoring Extn
24th Apr 20204:36 pmRNSPrice Monitoring Extension
24th Apr 20202:05 pmRNSSecond Price Monitoring Extn
24th Apr 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:40 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:35 pmRNSPrice Monitoring Extension
23rd Apr 202010:18 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.